Assessment of Rose Bengal Photodynamic Therapy on Viability and Proliferation of Human Keratolimbal Epithelial and Stromal Cells In Vitro
Klinische Monatsblätter für Augenheilkunde · 01.08.2024 · 241 (08) · 972-981
DOI: 10.1055/a-2038-8899 ↗Kurz gefasst
Fachartikel in der Zeitschrift Klinische Monatsblätter für Augenheilkunde, erschienen am 01.08.2024. Verfasst von Ning Chai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Rolf M. Schwiete Center for Limbal Stem Cell and Aniridia Research, Saarland University, Homburg/Saar, Germany. Hauptthemen laut MEDLINE: Photochemotherapy, Rose Bengal, Cell Proliferation, Cell Survival. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Abstract (Originalsprache)
Purpose
To investigate the effect of Rose Bengal photodynamic therapy (RB-PDT) on viability and proliferation of human limbal epithelial stem cells (T-LSCs), human corneal epithelial cells (HCE-T), human limbal fibroblasts (LFCs), and human normal and keratoconus fibroblasts (HCFs and KC-HCFs) in vitro.
Methods
T-LSCs and HCE-T cell lines were used in this research. LFCs were isolated from healthy donor corneal limbi (n = 5), HCFs from healthy human donor corneas (n = 5), and KC-HCFs from penetrating keratoplasties of keratoconus patients (n = 5). After cell culture, RB-PDT was performed using 0.001% RB concentration and 565 nm wavelength illumination with 0.14 to 0.7 J/cm2 fluence. The XTT and the BrdU assays were used to assess cell viability and proliferation 24 h after RB-PDT.
Results
RB or illumination alone did not change cell viability or proliferation in any of the cell types (p ≥ 0.1). However, following RB-PDT, viability decreased significantly from 0.17 J/cm2 fluence in HCFs (p < 0.001) and KC-HCFs (p < 0.0001), and from 0.35 J/cm2 fluence in T-LSCs (p < 0.001), HCE-T (p < 0.05), and LFCs ((p < 0.0001). Cell proliferation decreased significantly from 0.14 J/cm2 fluence in T-LSCs (p < 0.0001), HCE-T (p < 0.05), and KC-HCFs (p < 0.001) and from 0.17 J/cm2 fluence in HCFs (p < 0.05). Regarding LFCs proliferation, no values could be determined by the BrdU assay.
Conclusions
Though RB-PDT seems to be a safe and effective treatment method in vivo, its dose-dependent phototoxicity on corneal epithelial and stromal cells has to be respected. The data and experimental parameters applied in this study may provide a reliable reference for future investigations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dr. Rolf M. Schwiete Center for Limbal Stem Cell and Aniridia Research, Saarland University, Homburg/Saar, Germany.
- Department of Ophthalmology, Saarland University Hospital and Saarland University, Faculty of Medicine, Homburg/Saar, Germany.
- Institute of Experimental Ophthalmology, Saarland University, Homburg/Saar, Germany.
- Department of Ophthalmology, Semmelweis University, Budapest, Hungary.
ORCID-Profile: Ning Chai, Zhen Li, Berthold Seitz
Zitieren
APA
Chai, N., Stachon, T., Nastaranpour, M., Li, Z., Seitz, B., Ulrich, M., Langenbucher, A., & Szentmáry, N. (2024). Assessment of Rose Bengal Photodynamic Therapy on Viability and Proliferation of Human Keratolimbal Epithelial and Stromal Cells In Vitro. Klinische Monatsblätter für Augenheilkunde, 241(08), 972-981. https://doi.org/10.1055/a-2038-8899
Vancouver
Chai N, Stachon T, Nastaranpour M, Li Z, Seitz B, Ulrich M, et al. Assessment of Rose Bengal Photodynamic Therapy on Viability and Proliferation of Human Keratolimbal Epithelial and Stromal Cells In Vitro. Klinische Monatsblätter für Augenheilkunde. 2024;241(08):972-981. doi:10.1055/a-2038-8899
BibTeX
@article{Chai2024,
author = {Chai, Ning and Stachon, Tanja and Nastaranpour, Mahsa and Li, Zhen and Seitz, Berthold and Ulrich, Myriam and Langenbucher, Achim and Szentmáry, Nóra},
title = {Assessment of Rose Bengal Photodynamic Therapy on Viability and Proliferation of Human Keratolimbal Epithelial and Stromal Cells In Vitro},
journal = {Klinische Monatsblätter für Augenheilkunde},
year = {2024},
volume = {241},
number = {08},
pages = {972--981},
doi = {10.1055/a-2038-8899}
}
EUVIMED